Phylogenetic analysis of VP2 gene of canine parvovirus and comparison with Indian and world isolates

G. KAUR, M. CHANDRA, P . N. DWIVEDI

Department of Veterinary Microbiology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana-141001 Punjab, India

Received June 12, 2015; revised July 22, 2015; accepted February 18, 2016

Summary. – Canine parvovirus (CPV) causes hemorrhagic enteritis, especially in young dogs, leading to high morbidity and mortality. It has four main antigenic types CPV-2, CPV-2a, CPV-2b and CPV-2c. Virus protein 2 (VP2) is the main capsid protein and mutations affecting VP2 gene are responsible for the evolution of various antigenic types of CPV. Full length VP2 gene from field isolates was amplified and cloned for sequence analysis. The sequences were submitted to the GenBank and were assigned Acc. Nos., viz. KP406928.1 for P12, KP406927.1 for P15, KP406930.1 for P32, KP406926.1 for Megavac-6 and KP406929.1 for NobivacDHIPI. Phylogenetic analysis indicated that the samples were forming a separate clad with vaccine strains. When the samples were compared with the world and Indian isolates, it was observed that samples formed a separate node indicating regional genetic variation in CPV.

Keywords: canine parvovirus; VP2 gene; cloning; sequence analysis; phylogenetic analysis

Introduction

Canine parvovirus (CPV) (the family Paroviridae, the genus Parovirus) is an important cause of severe enteritis and systemic disease in dogs throughout the world. It spreads rapidly in the domestic as well as wild population of canines. CPV-2 was first recognised in 1978 (Carmichael et al., 1994) and antigenic variants of CPV-2, viz. CPV-2a, CPV-2b, CPV-2c, have been circulating in dog populations worldwide since then (Decaro et al., 2006). The origin of CPV is poorly understood and is thought to have phylogenetically originated from the feline panleukopenia virus or a very closely related carnivore parvovirus of feral canids like foxes and mink (Mochizuki et al., 2008). CPV possesses a high genetic substitution rate, which is responsible for its antigenic evolution and rapid displacement of old by new antigenic variants (Shackelton et al., 2005). In India, CPV was first reported in 1982 (Ramadass and Khader, 1982) and since then a large number of outbreaks have been reported from different parts of India in dogs involving CPV variants, viz. 2a, 2b and 2c (Biswas et al., 2006; Chinchkar et al., 2006; Nandi et al., 2009a,b; Singh et al., 2014).

The genome of CPV is approximately 5.3kb and has two open reading frames (ORFs); ORF1 and ORF2. ORF1 encodes two non-structural proteins, NS1 and NS2, and ORF2 encodes two capsid proteins, VP1 and VP2 (Ying et al., 2009). VP2 has an important role in determination of antigenicity of CPV (Phromnoi et al., 2010) and thus, mutations affecting VP2 are mainly responsible for the evolution of different antigenic variants of CPV (Mochizuki et al., 1993).

Therefore, sequencing and phylogenetic analysis of full length VP2 gene will provide information on the prevailing antigenic types of CPV in Ludhiana district of Punjab, India and its comparison with vaccines will provide information on the escape mutants in clinical cases of CPV.

Materials and Methods

Amplification of full length VP2 gene. For the amplification of full length VP2 gene of CPV, a total of 30 samples i.e. rectal swabs
detected positive via PCR and nested PCR, were selected from a total of 100 samples collected from dogs exhibiting clinical signs of CPV, viz. gastroenteritis, hemorrhagic enteritis, pyrexia etc., from small animal veterinary clinics, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab from June 2013 till January 2014. All rectal swabs were kept at 4°C till further use. In addition, two commercially available vaccines [Nobivac DHPPi (Intervet, Pvt. Ltd.) and Megavac-6 (Indian Immunologicals)] procured from local market in Ludhiana were used for the amplification of VP2 gene. DNA was extracted from the samples and the two vaccines using the phenol-chloroform extraction method (Sambrook and Russell, 2001).

**Primer designing.** The primer pairs for the amplification of full length VP2 gene were designed using Primer3 (Rozen and Skaletsky, 2007) (accession no. M19296.1) (Table 1).

**Polymerase chain reaction (PCR).** The PCR was set up by adding 1 μl of the template DNA, 10 μl of 5X long Amp reaction buffer (with 2 mmol/l MgSO₄), 1 μl of forward and reverse primer (20 pm/μl each), 1 μl of dNTPs mix (10 mmol/l each), 0.5 μl of MgCl₂ (50mmol/l), 2.5 U LongAmp Hot start Taq DNA polymerase and 72°C for 150 sec and a final elongation at 72°C for 10 min. The reaction was made up to 50 μl using nuclease free water. The PCR products were run in 1% agarose at 5 volts/cm along with Gene Ruler ladder 1Kb (New England Biolabs, USA) and the gel was visualized and photographed using Gel documentation system (AlphaImager, USA).

**Cloning of full length VP2 gene.** The samples, in which PCR amplified VP2 gene were, were first cleaned up using an UltraClean® 6 Minute Mini plasmid prep kit (Mo Bio Labs., Inc. USA). The recombinant plasmid was gel electrophoresed using 1.5% agarose at 5 volts/cm along with Gene Ruler ladder 1Kb (New England Biolabs, USA) and under following conditions: 35 cycles of denaturation at 94°C for 60 sec, annealing at 58°C for 60 sec, elongation at 72°C for 150 sec and a final elongation at 72°C for 10 min. The PCR products were run using 1% agarose at 5 volts/cm with Gene Ruler ladder 1Kb (New England Biolabs, USA) and the gel was visualized and photographed using Gel documentation system (Alphalmager, USA).

**Table 1. Primers for the amplification of full length VP2 gene of CPV**

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
<th>Acc. No.</th>
<th>Position in genome</th>
<th>Annealing temperature (°C)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VP2 GMCOM F</td>
<td>5'-GGTCAACCTGCTGTCAGAAA-3'</td>
<td>M19296.1 Whole genome of CPV</td>
<td>2816-2835</td>
<td>58</td>
<td>1710</td>
</tr>
<tr>
<td>VP2 GMCOM R</td>
<td>5'-AGGTGCTATTGAGATTTTCAT-3'</td>
<td></td>
<td>4525-4503</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Approximately three white colonies from LB agar plates were inoculated in 10 ml of LB broth with 100 μg ampicillin/ml and incubated in a shaker incubator (Thermo Scientific, USA) at 37°C overnight for plasmid extraction. The plasmid was extracted using an UltraClean® 6 Minute Mini plasmid prep kit (Mo Bio Labs., Inc. USA). The recombinant plasmid was gel electrophoresed using 1.5% agarose at 5 volts/cm along with Gene Ruler ladder 1Kb (New England Biolabs, USA) and the gel was visualized and photographed using Gel documentation system (Alphalmager, USA) for confirmation.

**Sequence analysis of full length VP2 gene.** Five recombinant plasmids, i.e. three from clinical samples (randomly selected) and two from vaccines, were sequenced at Invitrogen (India) and submitted to NCBI. These were analysed and compared with the available CPV sequences in GenBank using BLAST and Multiple sequence alignment software (Clustal Omega). Phylogenetic analysis of the sequences was also done using Mega6 (Tamura et al., 2013). These sequences were compared with the available Indian and world CPV VP2 sequences for phylogenetic analysis using Mega6 (Tamura et al., 2013).

**Results**

Full length VP2 gene of CPV was amplified from a total of 30 clinical samples and two vaccines using the designed primers that amplified a 1710 bp product (Fig. 1). The cleaned up PCR product was confirmed by agarose gel electrophoresis. After ligation and transformation of the cleaned PCR product, plasmid of approximately 4725bp (3015+1710bp) was obtained.

Out of these 30 recombinant plasmids, five recombinant plasmids, i.e. three of samples and two of vaccines, were sequenced at Invitrogen (India). When analysed using BLAST and multiple sequence alignment (Clustal Omega), multiple sequence alignment of the nucleotide sequences of the samples (P12, P15, P32) and the vaccines (Nobivac DHPPi and Megavac-6) revealed that all the samples belonged to the CPV-2a antigenic type but the vaccine was not found to be of the same type. Phylogenetic analysis of nucleotide
PCR for the amplification of VP2 gene of CPV
Gene ruler 1Kb (M). Positive control (1). Negative control (2). Samples (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14).

Fig. 2
Phylogenetic analysis of cloned VP2 gene of CPV samples and vaccines with Indian (a) and world (b) isolates using Mega6
(a) Scale of tree (5). Number of sequences compared (32+5). (b) Scale of tree (2). Number of sequences compared (21+5).
sequences from samples and vaccine strains revealed that all sequences in the present study formed a separate node from rest of the Indian (Fig. 2a) and worldwide isolates (Fig. 2b). This indicates a regional variation in the CPV isolates, since the clinical samples in this study were from dogs in Ludhiana district of Punjab.

Three sequences from the samples and the two sequences from vaccines were submitted to the GenBank and were assigned GenBank Acc. Nos. KP406928.1 for sample P12, KP406927.1 for sample P15, KP406930.1 for sample P32, KP406926.1 for Megavac-6 and KP406929.1 for NobivacDHPPi.

Based on the BLAST comparison of the sample and vaccines sequences, we found that all had 100% homology with the Canine Parvovirus.

Discussion

Canine parvovirus has emerged as one of the most important diseases of pups in recent years. The virus is prone to genetic evolution and has undergone several mutations, which has led to several antigenic variants of CPV-2 that have replaced the original CPV-2 (MohanRaj et al., 2010). There are currently three main antigenic variants, i.e. 2a, 2b and 2c, circulating in the dog population worldwide (Decaro et al., 2012). Majer-Dziedzic et al. (2011) reported that the mutations in the original CPV-2 strains and the appearance of the variants (2a, 2b and 2c) is due to the specific amino acid changes mainly in the capsid protein VP2. The VP2 is the immunodominant protein of CPV and is important in the determination of antigenic types based on the epitopes located on the VP2 protein. Thus, the mutations affecting VP2 are mainly responsible for the evolution of different antigenic variants of CPV (MohanRaj et al., 2010). Moreover, as this gene is under positive selection in CPV, it results in a significantly elevated rate of molecular evolution (Hoelzer et al., 2008). Thus, full length VP2 gene was amplified, sequenced and phylogenetically analysed to study the changes, if any, in the VP2 gene from the isolates circulating in the region under study so that prevailing antigenic types of CPV in dogs may be known.

The sequence analysis of the isolates in our study revealed that they belonged to the CPV-2a type. In India, Chinchkar et al. (2006) studied the epidemiology of CPV infection in dogs and found that CPV 2a was predominant over CPV 2b variant in Central and Southern India, whereas Parthibhan et al. (2012) reported CPV 2b as the major type in Tamil Nadu, India. Nowadays it has been observed that new types of CPV have been reported, viz. New CPV-2a, New CPV-2b etc., which are antigenically different from the earlier reported CPV types, and hence continuous surveillance is required. Thus, different studies in India have revealed that different variants of CPV are prevailing in different regions of India.

Similarly, the trend of change in the CPV variants has been observed around the world. Perez et al. (2012) showed that frequency of CPV-2a increased in a dog population from Uruguay, where CPV-2c was prevalent indicating change in variants. Similarly Xu et al. (2013) found that most of the isolates belonged to CPV-2a and found nucleotide identities of 98.8–100%, whereas the amino acid similarities were 99.6–100%. In similar studies conducted by Jing et al. (2011) in China and Yoon et al. (2009) in Korea, maximum number of isolates sequenced belonged to CPV-2a type. It has been observed that there is a dynamic change in CPV variants, stressing the need for more surveillance programs.

This study concludes that full length VP2 gene was successfully cloned (Acc. No. is KP406928.1 for P12, KP406927.1 for P15, KP406930.1 for P32, KP406926.1 for Megavac-6 and KP406929.1 for NobivacDHPPi) and sequence analysis revealed the samples belonged to CPV 2a. The samples were forming a separate clad among the Indian sequences indicating evolution in CPV. More surveillance studies are needed to further understand the evolution and regional variation among CPV types.

Acknowledgements. The authors are thankful to the University Grant Commission (UGC), New Delhi for the financial support (Grant No. 41-1170/2012(SR)) and Director of Research, GADVASU for providing the research facilities.

References


Hoelzer K, Shackleton LA, Holmes EC, Parrish CR (2008): Within-host genetic diversity of endemic and emerging parvovi-


